 Daniel Sherbenou
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 24 | 2026 | 309 | 8.670 |
Why?
| | Drug Resistance, Neoplasm | 10 | 2026 | 881 | 2.110 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1511 | 2.050 |
Why?
| | Immunoconjugates | 3 | 2020 | 138 | 1.380 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2025 | 127 | 1.270 |
Why?
| | Thalidomide | 3 | 2024 | 43 | 1.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2026 | 1965 | 1.030 |
Why?
| | Interferon Regulatory Factors | 2 | 2024 | 44 | 0.980 |
Why?
| | Leukocyte Common Antigens | 1 | 2026 | 87 | 0.960 |
Why?
| | Immunotherapy, Adoptive | 2 | 2026 | 342 | 0.920 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2024 | 167 | 0.900 |
Why?
| | Fusion Proteins, bcr-abl | 4 | 2010 | 68 | 0.890 |
Why?
| | Osteolysis | 1 | 2025 | 16 | 0.870 |
Why?
| | Immunoglobulin Light Chains | 1 | 2025 | 52 | 0.860 |
Why?
| | Ikaros Transcription Factor | 1 | 2024 | 23 | 0.840 |
Why?
| | Protein Kinase Inhibitors | 7 | 2025 | 980 | 0.800 |
Why?
| | Ribosomes | 1 | 2025 | 196 | 0.800 |
Why?
| | Piperazines | 5 | 2010 | 378 | 0.780 |
Why?
| | Pyrimidines | 5 | 2010 | 520 | 0.730 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 455 | 0.700 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 452 | 0.700 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2024 | 130 | 0.680 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 1150 | 0.670 |
Why?
| | Hydrazines | 1 | 2021 | 37 | 0.660 |
Why?
| | T-Lymphocytes | 2 | 2026 | 1996 | 0.650 |
Why?
| | Cell Line, Tumor | 9 | 2026 | 3537 | 0.640 |
Why?
| | Membrane Cofactor Protein | 2 | 2018 | 14 | 0.640 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2207 | 0.640 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.640 |
Why?
| | ADP-ribosyl Cyclase 1 | 4 | 2024 | 42 | 0.620 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 700 | 0.610 |
Why?
| | Triazoles | 1 | 2021 | 184 | 0.600 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 917 | 0.540 |
Why?
| | Antibodies, Bispecific | 3 | 2026 | 69 | 0.540 |
Why?
| | Antibodies, Neoplasm | 2 | 2018 | 34 | 0.530 |
Why?
| | B-Cell Maturation Antigen | 2 | 2026 | 17 | 0.450 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 201 | 0.430 |
Why?
| | Medical Oncology | 3 | 2026 | 338 | 0.400 |
Why?
| | Dexamethasone | 3 | 2021 | 366 | 0.390 |
Why?
| | Immunotherapy | 2 | 2017 | 667 | 0.390 |
Why?
| | Mutation | 4 | 2010 | 4093 | 0.390 |
Why?
| | Humans | 36 | 2026 | 145491 | 0.330 |
Why?
| | src Homology Domains | 1 | 2010 | 35 | 0.320 |
Why?
| | Mice | 9 | 2026 | 18338 | 0.300 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1439 | 0.300 |
Why?
| | Benzamides | 6 | 2018 | 224 | 0.300 |
Why?
| | Imatinib Mesylate | 5 | 2010 | 77 | 0.290 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 929 | 0.280 |
Why?
| | Oligopeptides | 2 | 2021 | 266 | 0.270 |
Why?
| | Transplantation Conditioning | 3 | 2020 | 191 | 0.270 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2020 | 103 | 0.270 |
Why?
| | Animals | 12 | 2026 | 38141 | 0.270 |
Why?
| | Sequence Deletion | 1 | 2008 | 191 | 0.260 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 431 | 0.260 |
Why?
| | Mutant Proteins | 1 | 2007 | 104 | 0.250 |
Why?
| | Stem Cell Transplantation | 1 | 2026 | 190 | 0.220 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2024 | 20 | 0.200 |
Why?
| | Bone Marrow | 3 | 2020 | 307 | 0.190 |
Why?
| | Male | 15 | 2026 | 72817 | 0.190 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2025 | 280 | 0.180 |
Why?
| | Cell Proliferation | 5 | 2020 | 2499 | 0.180 |
Why?
| | Lymphoma, B-Cell | 1 | 2024 | 137 | 0.180 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 443 | 0.180 |
Why?
| | Lymphoma | 1 | 2024 | 234 | 0.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 994 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 359 | 0.170 |
Why?
| | Sulfonamides | 1 | 2025 | 581 | 0.160 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 409 | 0.160 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2020 | 50 | 0.160 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 38 | 0.160 |
Why?
| | Graft vs Host Disease | 2 | 2020 | 281 | 0.160 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1321 | 0.160 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 191 | 0.160 |
Why?
| | Primary Cell Culture | 1 | 2020 | 172 | 0.160 |
Why?
| | Heterografts | 1 | 2020 | 143 | 0.160 |
Why?
| | Drug Synergism | 1 | 2020 | 353 | 0.150 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 420 | 0.150 |
Why?
| | Aged | 10 | 2026 | 26125 | 0.150 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 883 | 0.140 |
Why?
| | Endoribonucleases | 1 | 2019 | 80 | 0.140 |
Why?
| | Thiotepa | 1 | 2018 | 21 | 0.140 |
Why?
| | Prognosis | 2 | 2025 | 4323 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 1058 | 0.130 |
Why?
| | Phenotype | 1 | 2026 | 3157 | 0.130 |
Why?
| | Middle Aged | 10 | 2026 | 36176 | 0.130 |
Why?
| | Prostate | 1 | 2018 | 158 | 0.130 |
Why?
| | Melphalan | 1 | 2017 | 43 | 0.130 |
Why?
| | Female | 13 | 2026 | 78763 | 0.130 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 119 | 0.120 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 272 | 0.120 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 196 | 0.120 |
Why?
| | Flow Cytometry | 1 | 2020 | 1156 | 0.120 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2016 | 80 | 0.120 |
Why?
| | Protein Structure, Tertiary | 3 | 2007 | 850 | 0.120 |
Why?
| | Gene Dosage | 1 | 2016 | 148 | 0.120 |
Why?
| | Salvage Therapy | 1 | 2017 | 165 | 0.120 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 210 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2021 | 11831 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2018 | 260 | 0.110 |
Why?
| | Adult | 9 | 2026 | 40707 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1269 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 439 | 0.100 |
Why?
| | Signal Transduction | 3 | 2020 | 5202 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2019 | 8326 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2018 | 923 | 0.080 |
Why?
| | Recurrence | 3 | 2019 | 1142 | 0.080 |
Why?
| | Prostatic Neoplasms | 1 | 2018 | 978 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2026 | 17269 | 0.080 |
Why?
| | Immunoblotting | 2 | 2008 | 294 | 0.080 |
Why?
| | Protein Kinases | 1 | 2010 | 314 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2026 | 737 | 0.070 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2008 | 41 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2008 | 5426 | 0.070 |
Why?
| | Philadelphia Chromosome | 1 | 2007 | 18 | 0.070 |
Why?
| | Tyrosine | 1 | 2008 | 219 | 0.060 |
Why?
| | Cell Line | 2 | 2010 | 2823 | 0.060 |
Why?
| | Janus Kinase 2 | 1 | 2006 | 29 | 0.060 |
Why?
| | RNA, Neoplasm | 1 | 2007 | 83 | 0.060 |
Why?
| | Myeloproliferative Disorders | 1 | 2006 | 21 | 0.060 |
Why?
| | Codon | 1 | 2007 | 93 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2007 | 158 | 0.060 |
Why?
| | Treatment Refusal | 1 | 2007 | 98 | 0.060 |
Why?
| | Remission Induction | 1 | 2007 | 309 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-abl | 1 | 2005 | 6 | 0.060 |
Why?
| | DNA Mutational Analysis | 1 | 2007 | 409 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 297 | 0.060 |
Why?
| | Blast Crisis | 1 | 2025 | 34 | 0.050 |
Why?
| | src-Family Kinases | 1 | 2005 | 92 | 0.050 |
Why?
| | Models, Molecular | 1 | 2010 | 1614 | 0.050 |
Why?
| | Protein Conformation | 1 | 2008 | 935 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2006 | 338 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 975 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2007 | 581 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1374 | 0.050 |
Why?
| | Phosphorylation | 1 | 2008 | 1707 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2008 | 4127 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2026 | 878 | 0.040 |
Why?
| | X-Box Binding Protein 1 | 1 | 2019 | 16 | 0.040 |
Why?
| | Bortezomib | 1 | 2019 | 54 | 0.040 |
Why?
| | Cohort Studies | 1 | 2010 | 5992 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2019 | 58 | 0.040 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2019 | 37 | 0.040 |
Why?
| | Androstenes | 1 | 2018 | 16 | 0.040 |
Why?
| | Therapeutics | 1 | 2018 | 14 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2820 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2018 | 70 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 118 | 0.030 |
Why?
| | Phenylthiohydantoin | 1 | 2018 | 44 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2018 | 60 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 23 | 0.030 |
Why?
| | Vidarabine | 1 | 2018 | 32 | 0.030 |
Why?
| | Young Adult | 2 | 2018 | 14192 | 0.030 |
Why?
| | Myocarditis | 1 | 2019 | 102 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2018 | 4 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2026 | 2950 | 0.030 |
Why?
| | Fetal Blood | 1 | 2020 | 325 | 0.030 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 74 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 782 | 0.030 |
Why?
| | Nitriles | 1 | 2018 | 205 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 133 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2017 | 211 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 863 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 974 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2017 | 298 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1332 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2018 | 667 | 0.030 |
Why?
| | beta Catenin | 1 | 2018 | 253 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1081 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1710 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2093 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 2006 | 419 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 686 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2862 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4283 | 0.020 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2006 | 5 | 0.020 |
Why?
| | Polycythemia Vera | 1 | 2006 | 8 | 0.020 |
Why?
| | Receptors, Erythropoietin | 1 | 2006 | 21 | 0.020 |
Why?
| | Polycythemia | 1 | 2006 | 25 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 90 | 0.020 |
Why?
| | Clone Cells | 1 | 2006 | 264 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 2005 | 38 | 0.010 |
Why?
| | Erythropoietin | 1 | 2006 | 100 | 0.010 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 90 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 321 | 0.010 |
Why?
| | Dasatinib | 1 | 2005 | 57 | 0.010 |
Why?
| | Time Factors | 2 | 2006 | 7171 | 0.010 |
Why?
| | Thiazoles | 1 | 2005 | 139 | 0.010 |
Why?
| | Point Mutation | 1 | 2005 | 242 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 511 | 0.010 |
Why?
| | Transfection | 1 | 2006 | 925 | 0.010 |
Why?
| | Fibrosis | 1 | 2006 | 551 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2005 | 335 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2006 | 1261 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2005 | 503 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1212 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2030 | 0.010 |
Why?
| | Stem Cells | 1 | 2005 | 626 | 0.010 |
Why?
|
|
Sherbenou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|